Pfizer Hemophilia presents new data at the World Federation of Hemophilia 2010 Congress

EurekAlert

BUENOS AIRES, ARGENTINA, July 9 Pfizer Inc, the world's leading biopharmaceutical company, today announced that the results of a number of hemophilia studies will be presented at the World Federation of Hemophilia (WFH) 2010 Congress taking place July 10-14, 2010, in Buenos Aires, Argentina. Key research includes a pre-clinical evaluation of recombinant factor Xa as a potential new approach to restoring hemostasis, as well as a study assessing the potential for an engineered recombinant factor VIIa molecule to improve therapeutic outcomes in mouse models of hemophilia. These presentations follow Pfizer's recent announcement about the creation of a new research unit focused on rare diseases, including hemophilia.

"We are very excited to present these data, which highlights the strength of our pipeline and our enduring commitment to provide recombinant products for the hemophilia community," says Brenda Cooperstone, M.D., vice president of clinical development and medical affairs for the Specialty Care Business Unit at Pfizer. "Our investigation of novel therapies for hemophilia treatment remains ongoing and we will continue to work closely with our partners—including the World Federation of Hemophilia—to help improve hemophilia care worldwide."

Early Research with Factor Xa and VIIa

Pfizer will present the results of a pre-clinical study in mice indicating that recombinant factor Xa therapy may provide a unique way to bypass deficiencies in the intrinsic pathway. Additional results from a preclinical study in mice suggest that a recombinant factor VIIa molecule with increased activity and duration of action may have the potential to improve inhibitor outcomes.

Additional Hemophilia Research from Pfizer at WFH

- New model of antibody-induced hemophilia A for the assessment of bypass therapies
- An electronic documentation system in Haemophilia provides otherwise unavailable feedback for continuous quality control first results from the Haemoassist® system
- A prospective registry of European hemophilia B patients receiving BeneFIX® (nonacog alfa, recombinant human factor IX) for usual use
- Two-year interim results of a non-interventional trial to assess the safety and efficacy of treatment with recombinant factor IX
- Safety and efficacy of B-domain-deleted recombinant FVIII final results of a 10 year pharmacovigilance study

Pfizer's Ongoing Commitment to the WFH and the Hemophilia Community

Pfizer will make a contribution to WFH at the meeting in support of the Twinning Program, which aims to increase the level of diagnosis and care for people with hemophilia by pairing emerging treatment centers and patient organizations with more established centers and organizations around the world. Wyeth, now part of Pfizer, has acted as the exclusive corporate sponsor of the world-renowned program since 2001, which currently has 32 Twinning partnerships worldwide. Historically, there have been 149 Twinnings. Pfizer will also host the annual reception for the Twinning Program.

SOURCE [1]

Source URL (retrieved on *07/10/2014 - 9:46am*):
http://www.mdtmag.com/news/2010/07/pfizer-hemophilia-presents-new-data-world-federation-hemophilia-2010-congress

Links:
[1] http://www.eurekalert.org/pub_releases/2010-07/epr-php070810.php